Evidence map›Paper›PMID 33099060›Full record

ArticleBiomaterials2021

Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice.

Mohammad Ariful Islam, Jamie Rice, Emma Reesor, Harshal Zope, Wei Tao, Michael Lim, Jianxun Ding, Yunhan Chen, Dike Aduluso, Bruce R Zetter and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 216 citations in OpenAlex.

  1. Bioactive lipid-derived nanoparticles for RNA delivery.Materials today (Kidlington, England) · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. mRNA vaccines as cancer therapies.Chinese medical journal · 2024
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Mohammad Ariful IslamCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jamie RiceVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Emma ReesorCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Harshal ZopeCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Wei TaoCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Michael LimCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jianxun DingCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Yunhan ChenCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Dike AdulusoCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Bruce R ZetterVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: bruce.zetter@childrens.harvard.edu.
Omid C FarokhzadCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: ofarokhzad@bwh.harvard.edu.
Jinjun ShiCenter for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: jshi@bwh.harvard.edu.
Harvard University · USBrigham and Women's Hospital · USBoston Children's Hospital · US

Funding

Systemic RNA Delivery to TumorsR01CA200900 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI SHI, JINJUN · 2016 to 2025
$5.5M
NCI NIH HHS R01 CA200900
6 · The paper itself

Abstract

Synthetic mRNA represents an exciting cancer vaccine technology for the implementation of effective cancer immunotherapy. However, inefficient in vivo mRNA delivery along with a requirement for immune co-stimulation present major hurdles to achieving anti-tumor therapeutic efficacy. Here, we demonstrate a proof-of-concept adjuvant-pulsed mRNA vaccine nanoparticle (NP) that is composed of an ovalbumin-coded mRNA and a palmitic acid-modified TLR7/8 agonist R848 (C16-R848), coated with a lipid-polyethylene glycol (lipid-PEG) shell. This mRNA vaccine NP formulation retained the adjuvant activity of encapsulated C16-R848 and markedly improved the transfection efficacy of the mRNA (>95%) and subsequent MHC class I presentation of OVA mRNA derived antigen in antigen-presenting cells. The C16-R848 adjuvant-pulsed mRNA vaccine NP approach induced an effective adaptive immune response by significantly improving the expansion of OVA-specific CD8

Indexed as

Cancer VaccinesNanoparticlesAnimalsCD8-Positive T-LymphocytesDendritic CellsMaleMiceMice, Inbred C57BLOvalbuminRNA, MessengerCancer VaccinesOvalbuminRNA, MessengerAdjuvant pulsationCancerImmunotherapymRNA vaccineNanoparticle

Identifiers

PMID33099060
PMCPMC7528902
OpenAlexW3089495849

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.